Legal & General Group PLC Exelixis, Inc. Transaction History

Legal & General Group PLC

  • $368 Billion
  • Q4 2024

A detailed history of Legal & General Group PLC transactions in Exelixis, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 576,058 shares of EXEL stock, worth $21.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
576,058
Previous 603,813 4.6%
Holding current value
$21.2 Million
Previous $15.7 Million 22.43%
% of portfolio
0.01%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
SELL
$25.39 - $36.46 $704,699 - $1.01 Million
-27,755 Reduced 4.6%
576,058 $19.2 Million
Q3 2024

Nov 14, 2024
SELL
$21.96 - $27.6 $382,894 - $481,233
-17,436 Reduced 2.81%
603,813 $15.7 Million
Q2 2024

Aug 14, 2024
SELL
$20.34 - $23.73 $1.09 Million - $1.28 Million
-53,803 Reduced 7.97%
621,249 $14 Million
Q1 2024

May 14, 2024
SELL
$20.17 - $23.93 $1.13 Million - $1.34 Million
-55,815 Reduced 7.64%
675,052 $16 Million
Q4 2023

Feb 15, 2024
SELL
$19.25 - $24.13 $378,166 - $474,033
-19,645 Reduced 2.62%
730,867 $17.5 Million
Q3 2023

Nov 14, 2023
SELL
$19.04 - $22.74 $499,228 - $596,242
-26,220 Reduced 3.38%
750,512 $16.4 Million
Q2 2023

Aug 14, 2023
SELL
$18.17 - $20.48 $575,643 - $648,826
-31,681 Reduced 3.92%
776,732 $14.8 Million
Q1 2023

May 15, 2023
BUY
$16.3 - $19.41 $431,526 - $513,860
26,474 Added 3.39%
808,413 $15.7 Million
Q4 2022

Feb 14, 2023
BUY
$14.96 - $17.39 $161,762 - $188,038
10,813 Added 1.4%
781,939 $12.5 Million
Q3 2022

Nov 14, 2022
BUY
$15.68 - $22.27 $46,491 - $66,030
2,965 Added 0.39%
771,126 $12.1 Million
Q2 2022

Aug 22, 2022
BUY
$17.44 - $23.16 $1.06 Million - $1.41 Million
60,994 Added 8.63%
768,161 $16 Million
Q1 2022

May 16, 2022
BUY
$17.03 - $22.67 $178,883 - $238,125
10,504 Added 1.51%
707,167 $16 Million
Q4 2021

Feb 14, 2022
SELL
$15.84 - $21.88 $208,200 - $287,590
-13,144 Reduced 1.85%
696,663 $12.7 Million
Q3 2021

Nov 15, 2021
BUY
$16.3 - $21.14 $861,846 - $1.12 Million
52,874 Added 8.05%
709,807 $15 Million
Q2 2021

Aug 12, 2021
SELL
$17.95 - $25.56 $1.09 Million - $1.55 Million
-60,745 Reduced 8.46%
656,933 $12 Million
Q1 2021

May 17, 2021
BUY
$20.53 - $25.22 $260,443 - $319,940
12,686 Added 1.8%
717,678 $16.2 Million
Q4 2020

Feb 12, 2021
SELL
$18.39 - $24.8 $370,613 - $499,794
-20,153 Reduced 2.78%
704,992 $14.1 Million
Q3 2020

Nov 13, 2020
BUY
$20.67 - $26.94 $359,244 - $468,217
17,380 Added 2.46%
725,145 $17.7 Million
Q2 2020

Aug 14, 2020
BUY
$16.46 - $27.42 $4.39 Million - $7.31 Million
266,516 Added 60.4%
707,765 $16.8 Million
Q1 2020

May 14, 2020
BUY
$14.46 - $21.8 $39,779 - $59,971
2,751 Added 0.63%
441,249 $7.6 Million
Q4 2019

Feb 13, 2020
BUY
$15.15 - $18.89 $590,592 - $736,388
38,983 Added 9.76%
438,498 $7.73 Million
Q3 2019

Nov 13, 2019
BUY
$17.68 - $22.65 $560,933 - $718,616
31,727 Added 8.63%
399,515 $7.07 Million
Q2 2019

Aug 14, 2019
BUY
$18.93 - $24.75 $352,760 - $461,216
18,635 Added 5.34%
367,788 $7.86 Million
Q1 2019

May 15, 2019
BUY
$19.6 - $24.76 $77,870 - $98,371
3,973 Added 1.15%
349,153 $8.31 Million
Q4 2018

Feb 15, 2019
BUY
$13.65 - $21.8 $253,439 - $404,760
18,567 Added 5.68%
345,180 $6.79 Million
Q3 2018

Nov 20, 2018
BUY
$15.87 - $22.4 $268,488 - $378,963
16,918 Added 5.46%
326,613 $5.79 Million
Q2 2018

Aug 10, 2018
BUY
$18.56 - $22.45 $2.82 Million - $3.41 Million
151,752 Added 96.08%
309,695 $6.67 Million
Q1 2018

May 17, 2018
BUY
$22.15 - $31.89 $50,502 - $72,709
2,280 Added 1.46%
157,943 $3.5 Million
Q4 2017

Feb 13, 2018
BUY
$24.23 - $30.93 $3.77 Million - $4.81 Million
155,663
155,663 $4.73 Million

Others Institutions Holding EXEL

# of Institutions
564
Shares Held
251M
Call Options Held
1.45M
Put Options Held
1.13M
View Full List

About EXELIXIS, INC.

EXEL Quotes by TradingView
  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $11.9B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email